DK2432798T3 - 17-hydroxy-17-pentaflourethyl-estra-4,9(10)-dien-11-aryl-derivat, fremgangsmåde til fremstilling heraf og anvendelse heraf til behandling af sygdomme - Google Patents

17-hydroxy-17-pentaflourethyl-estra-4,9(10)-dien-11-aryl-derivat, fremgangsmåde til fremstilling heraf og anvendelse heraf til behandling af sygdomme

Info

Publication number: DK2432798T3
Authority: DK; Denmark
Prior art keywords: pentaflourethyl; estra; dien; diseases; hydroxy
Prior art date: 2009-07-20

Application number

DK10735198.3T

Other languages

English (en)

Inventor

Wolfgang Schwede

Ulrich Klar

Carsten Moeller

Andrea Rotgeri

Wilhelm Bone

Original Assignee

Bayer Ip Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-07-20

Filing date

2010-07-07

Publication date

2013-07-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43383964&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2432798(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-07-07 Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh

2013-07-01 Application granted granted Critical

2013-07-01 Publication of DK2432798T3 publication Critical patent/DK2432798T3/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

DK10735198.3T 2009-07-20 2010-07-07 17-hydroxy-17-pentaflourethyl-estra-4,9(10)-dien-11-aryl-derivat, fremgangsmåde til fremstilling heraf og anvendelse heraf til behandling af sygdomme DK2432798T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102009034362A DE102009034362A1 (de)	2009-07-20	2009-07-20	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
PCT/EP2010/004149 WO2011009531A2 (de)	2009-07-20	2010-07-07	17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten

Publications (1)

Publication Number	Publication Date
DK2432798T3 true DK2432798T3 (da)	2013-07-01

Family

ID=43383964

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK12194455.7T DK2623510T3 (da)	2009-07-20	2010-07-07	17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivater, fremgangsmåde til fremstilling heraf og deres anvendelse til behandling af sygdomme
DK17176264.4T DK3252069T3 (da)	2009-07-20	2010-07-07	(11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentalfuoromethyl)estra-4,9-dien-3-oner til behandling af sygdomme
DK10735198.3T DK2432798T3 (da)	2009-07-20	2010-07-07	17-hydroxy-17-pentaflourethyl-estra-4,9(10)-dien-11-aryl-derivat, fremgangsmåde til fremstilling heraf og anvendelse heraf til behandling af sygdomme

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK12194455.7T DK2623510T3 (da)	2009-07-20	2010-07-07	17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivater, fremgangsmåde til fremstilling heraf og deres anvendelse til behandling af sygdomme
DK17176264.4T DK3252069T3 (da)	2009-07-20	2010-07-07	(11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentalfuoromethyl)estra-4,9-dien-3-oner til behandling af sygdomme

Country Status (48)

Country	Link
US (4)	US20120149670A1 (da)
EP (4)	EP3252069B1 (da)
JP (3)	JP5795312B2 (da)
KR (2)	KR101687853B1 (da)
CN (1)	CN102482317B (da)
AR (1)	AR077491A1 (da)
AU (1)	AU2010275849B2 (da)
BR (1)	BR112012001344B8 (da)
CA (1)	CA2768407C (da)
CL (1)	CL2012000166A1 (da)
CO (1)	CO6491067A2 (da)
CR (2)	CR20170091A (da)
CU (1)	CU20120012A7 (da)
CY (3)	CY1114260T1 (da)
DE (1)	DE102009034362A1 (da)
DK (3)	DK2623510T3 (da)
DO (2)	DOP2012000015A (da)
EA (2)	EA021946B1 (da)
EC (2)	ECSP12011616A (da)
ES (3)	ES2648292T3 (da)
GT (1)	GT201200012A (da)
HK (1)	HK1171456A1 (da)
HN (1)	HN2012000137A (da)
HR (3)	HRP20130558T1 (da)
HU (2)	HUE043757T2 (da)
IL (1)	IL216967B (da)
IN (1)	IN2012DN00598A (da)
JO (2)	JO3009B1 (da)
LT (2)	LT3252069T (da)
MA (1)	MA33445B1 (da)
ME (2)	ME03400B (da)
MX (2)	MX2012000930A (da)
MY (1)	MY179447A (da)
NO (1)	NO2623510T3 (da)
NZ (2)	NZ623417A (da)
PE (2)	PE20121085A1 (da)
PL (3)	PL2432798T3 (da)
PT (3)	PT2623510T (da)
RS (1)	RS52811B (da)
SG (3)	SG177519A1 (da)
SI (3)	SI2623510T1 (da)
TN (1)	TN2012000028A1 (da)
TR (1)	TR201908600T4 (da)
TW (1)	TWI505830B (da)
UA (1)	UA106502C2 (da)
UY (1)	UY32791A (da)
WO (1)	WO2011009531A2 (da)
ZA (1)	ZA201201222B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102009034366A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de)	2009-07-21	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de)	2009-07-21	2011-02-10	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de)	2010-02-10	2011-08-11	Bayer Schering Pharma Aktiengesellschaft, 13353	Progesteronrezeptorantagonisten
DE102010007722A1 (de)	2010-02-10	2011-08-11	Bayer Schering Pharma Aktiengesellschaft, 13353	Progesteronrezeptorantagonisten
DE102011088270A1 (de)	2011-12-12	2013-06-13	Bayer Intellectual Property Gmbh	(11ß ,17ß)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on zur Behandlung von Morbus Charcot Marie Toot
EP2983671B1 (en)	2013-04-11	2018-10-24	Bayer Pharma Aktiengesellschaft	Progesterone receptor antagonist dosage form
US9096641B2 (en)	2013-06-05	2015-08-04	Evestra, Inc.	Imidazolyl progesterone antagonists
CN107635562A (zh) *	2015-05-18	2018-01-26	拜耳医药股份有限公司	选择性孕酮受体调节剂（sprm）方案
EP3214092A1 (en)	2016-03-04	2017-09-06	Bayer Pharma Aktiengesellschaft	Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
EP3384913A1 (en)	2017-04-03	2018-10-10	Bayer Pharma Aktiengesellschaft	Selective progesterone receptor modulators and stabilized estrogen level in patient
CN111225671A (zh) *	2017-10-26	2020-06-02	苏州科睿思制药有限公司	一种选择性孕酮受体调节剂的晶体及其制备方法
US20240139274A1 (en)	2022-03-01	2024-05-02	Altin Biosciences Corporation	Crila® and egcg compositions for treatment of fibroids

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA8231B (en)	1981-01-09	1982-11-24	Roussel Uclaf	New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
DE3347126A1 (de) *	1983-12-22	1985-07-11	Schering AG, 1000 Berlin und 4709 Bergkamen	11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) *	1986-03-26	1989-05-26	Roussel Uclaf	Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5272140A (en)	1987-01-23	1993-12-21	Akzo N.V.	11-aryl steroid derivatives
FR2620707B1 (fr)	1987-09-18	1989-12-08	Roussel Uclaf	Nouveaux steroides comportant un cycle spirannique a 3, 4 ou 6 chainons en position 17, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US4954490A (en)	1988-06-23	1990-09-04	Research Triangle Institute	11 β-substituted progesterone analogs
FR2644789B1 (fr)	1989-03-22	1995-02-03	Roussel Uclaf	Nouveaux steroides 19-nor, 3-ceto comportant une chaine en 17 aminosubstituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
DE59010853D1 (de)	1989-08-04	1998-12-03	Schering Ag	11 Beta-Aryl-gona-4,9-dien-3-one
US5407928A (en)	1990-08-15	1995-04-18	Schering Aktiengesellschaft	11β-aryl-gona-4,9-dien-3-ones
CA2100514C (en) *	1992-07-29	2005-03-29	Johannes A. M. Hamersma	17-spiromethylene steroids
FR2718354B1 (fr)	1994-04-08	1996-05-03	Roussel Uclaf	Application des composés antiglucocorticoïde pour la préparation de médicaments destinés à la prévention ou au traitement des manifestations liées au syndrome de sevrage des narcotiques et les compositions les renfermant.
DE4426601A1 (de)	1994-07-27	1996-02-01	Schering Ag	Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
PT792152E (pt)	1994-11-22	2004-07-30	Balance Pharmaceuticals Inc	Metodos de contracepcao
ES2152671T3 (es)	1996-05-01	2001-02-01	Us Gov Health & Human Serv	Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales.
WO1998005679A2 (en)	1996-08-05	1998-02-12	Duke University	Mixed agonists of the progesterone receptor and assays therefor
DE19635525A1 (de)	1996-08-20	1998-02-26	Schering Ag	7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
FR2757400B1 (fr)	1996-12-19	1999-12-17	Hoechst Marion Roussel Inc	Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
DE19706061A1 (de)	1997-02-07	1998-08-13	Schering Ag	Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010016578A1 (en)	1997-06-18	2001-08-23	Balance Pharmaceuticals, Inc.	Compositions and methods for contraception and for treatment of benign gynecological disorders
JPH11171774A (ja)	1997-12-05	1999-06-29	Kyowa Hakko Kogyo Co Ltd	血球増多剤
PE20000129A1 (es)	1997-12-23	2000-03-11	Schering Ag	11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa
US6020328A (en)	1998-03-06	2000-02-01	Research Triangle Institute	20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
WO1999053924A1 (fr)	1998-04-17	1999-10-28	Kyowa Hakko Kogyo Co., Ltd.	Agent analgesique
US6172052B1 (en) *	1998-12-04	2001-01-09	Research Triangle Institute	17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6476079B1 (en)	1999-12-23	2002-11-05	Leiras Oy	Devices for the delivery of drugs having antiprogestinic properties
EP1157996A1 (de)	2000-05-23	2001-11-28	JENAPHARM GmbH	Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
DE60124289T2 (de)	2000-09-18	2007-09-06	Applied Research Systems Ars Holding N.V.	Verfahren zur herstellung von 21-hydroxy-6,19-oxidoprogesteron (21oh-6op)
WO2002032429A2 (en)	2000-10-18	2002-04-25	Schering Aktiengesellschaft	Use of inhibitors of progesterone receptor for treating cancer
WO2002032430A1 (en)	2000-10-18	2002-04-25	Schering Aktiengesellschaft	Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
DE10051609A1 (de)	2000-10-18	2002-05-02	Schering Ag	Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
US20020143000A1 (en) *	2001-01-09	2002-10-03	Christa Hegele-Hartung	Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
NZ526908A (en) *	2001-01-09	2005-07-29	Schering Ag	The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
DE10159217A1 (de)	2001-11-27	2003-06-05	Schering Ag	17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
DE10221034A1 (de)	2002-05-03	2003-11-20	Schering Ag	17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
ATE307823T1 (de)	2002-05-03	2005-11-15	Schering Ag	17a-fluoralkyl-11beta-benzaldoxim-steroide, verfahren zu deren herstellung, diese steroide enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
PT1768625E (pt)	2004-07-09	2011-04-18	Hra Pharma Lab	Composições de libertação sustida contendo moduladores do receptor da progesterona
WO2006101009A1 (ja)	2005-03-18	2006-09-28	Hirose Engineering Co., Ltd.	ナイルレッド系赤色発光化合物、及び発光素子
US20070105828A1 (en)	2005-08-19	2007-05-10	Glenmark Pharmaceuticals Limited	Novel polymorph form M of mifepristone and process for its preparation
EP1862468A1 (de)	2006-06-02	2007-12-05	Bayer Schering Pharma Aktiengesellschaft	Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102006054535A1 (de)	2006-11-15	2008-05-21	Bayer Schering Pharma Aktiengesellschaft	Progesteronrezeptorantagonisten
US20090075989A1 (en) *	2006-12-21	2009-03-19	Wolfgang Schwede	Non-steroidal progesterone receptor modulators
BRPI0714690A2 (pt)	2007-03-01	2012-12-25	Prs Mediterranean Ltd	sistema de confinamento celular em multicamadas resistente a uv
EP2123279A1 (de)	2008-05-14	2009-11-25	Bayer Schering Pharma Aktiengesellschaft	Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034362A1 (de) *	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten

2009
- 2009-07-20 DE DE102009034362A patent/DE102009034362A1/de not_active Withdrawn
2010
- 2010-07-07 MY MYPI2012000105A patent/MY179447A/en unknown
- 2010-07-07 LT LTEP17176264.4T patent/LT3252069T/lt unknown
- 2010-07-07 CR CR20170091A patent/CR20170091A/es unknown
- 2010-07-07 AU AU2010275849A patent/AU2010275849B2/en not_active Ceased
- 2010-07-07 HU HUE17176264A patent/HUE043757T2/hu unknown
- 2010-07-07 KR KR1020127001509A patent/KR101687853B1/ko active IP Right Grant
- 2010-07-07 CA CA2768407A patent/CA2768407C/en active Active
- 2010-07-07 BR BR112012001344A patent/BR112012001344B8/pt not_active IP Right Cessation
- 2010-07-07 EA EA201200121A patent/EA021946B1/ru not_active IP Right Cessation
- 2010-07-07 SG SG2012000725A patent/SG177519A1/en unknown
- 2010-07-07 NZ NZ623417A patent/NZ623417A/en not_active IP Right Cessation
- 2010-07-07 MX MX2012000930A patent/MX2012000930A/es active IP Right Grant
- 2010-07-07 ES ES12194455.7T patent/ES2648292T3/es active Active
- 2010-07-07 PL PL10735198T patent/PL2432798T3/pl unknown
- 2010-07-07 PT PT121944557T patent/PT2623510T/pt unknown
- 2010-07-07 EP EP17176264.4A patent/EP3252069B1/de active Active
- 2010-07-07 EP EP12194455.7A patent/EP2623510B1/de active Active
- 2010-07-07 EP EP17176265.1A patent/EP3272763A1/de not_active Withdrawn
- 2010-07-07 PT PT107351983T patent/PT2432798E/pt unknown
- 2010-07-07 RS RS20130259A patent/RS52811B/en unknown
- 2010-07-07 SG SG10201404159VA patent/SG10201404159VA/en unknown
- 2010-07-07 PL PL17176264T patent/PL3252069T3/pl unknown
- 2010-07-07 JP JP2012520921A patent/JP5795312B2/ja not_active Expired - Fee Related
- 2010-07-07 EP EP10735198A patent/EP2432798B1/de active Active
- 2010-07-07 PL PL12194455T patent/PL2623510T3/pl unknown
- 2010-07-07 EA EA201301263A patent/EA025150B1/ru not_active IP Right Cessation
- 2010-07-07 LT LTEP12194455.7T patent/LT2623510T/lt unknown
- 2010-07-07 PT PT17176264T patent/PT3252069T/pt unknown
- 2010-07-07 SI SI201031582T patent/SI2623510T1/sl unknown
- 2010-07-07 WO PCT/EP2010/004149 patent/WO2011009531A2/de active Application Filing
- 2010-07-07 KR KR1020167020690A patent/KR101854059B1/ko active IP Right Grant
- 2010-07-07 DK DK12194455.7T patent/DK2623510T3/da active
- 2010-07-07 NZ NZ597639A patent/NZ597639A/en not_active IP Right Cessation
- 2010-07-07 CN CN201080032941.3A patent/CN102482317B/zh active Active
- 2010-07-07 DK DK17176264.4T patent/DK3252069T3/da active
- 2010-07-07 IN IN598DEN2012 patent/IN2012DN00598A/en unknown
- 2010-07-07 ES ES10735198T patent/ES2416461T3/es active Active
- 2010-07-07 ES ES17176264T patent/ES2730209T3/es active Active
- 2010-07-07 TR TR2019/08600T patent/TR201908600T4/tr unknown
- 2010-07-07 ME MEP-2019-131A patent/ME03400B/me unknown
- 2010-07-07 ME MEP-2013-69A patent/ME01534B/me unknown
- 2010-07-07 PE PE2012000076A patent/PE20121085A1/es active IP Right Grant
- 2010-07-07 US US13/376,512 patent/US20120149670A1/en not_active Abandoned
- 2010-07-07 MA MA34552A patent/MA33445B1/fr unknown
- 2010-07-07 UA UAA201201277A patent/UA106502C2/uk unknown
- 2010-07-07 SG SG10201811830PA patent/SG10201811830PA/en unknown
- 2010-07-07 DK DK10735198.3T patent/DK2432798T3/da active
- 2010-07-07 NO NO12194455A patent/NO2623510T3/no unknown
- 2010-07-07 SI SI201030255T patent/SI2432798T1/sl unknown
- 2010-07-07 HU HUE12194455A patent/HUE037339T2/hu unknown
- 2010-07-07 PE PE2016002208A patent/PE20170084A1/es unknown
- 2010-07-07 SI SI201031890T patent/SI3252069T1/sl unknown
- 2010-07-09 TW TW099122758A patent/TWI505830B/zh active
- 2010-07-16 UY UY0001032791A patent/UY32791A/es not_active Application Discontinuation
- 2010-07-18 JO JOP/2010/0255A patent/JO3009B1/ar active
- 2010-07-20 AR ARP100102636A patent/AR077491A1/es active IP Right Grant
2011
- 2011-12-13 US US13/324,912 patent/US8278469B2/en active Active
- 2011-12-14 IL IL216967A patent/IL216967B/en active IP Right Grant
2012
- 2012-01-19 TN TNP2012000028A patent/TN2012000028A1/en unknown
- 2012-01-20 MX MX2013006080A patent/MX338217B/es unknown
- 2012-01-20 CR CR20120040A patent/CR20120040A/es unknown
- 2012-01-20 HN HN2012000137A patent/HN2012000137A/es unknown
- 2012-01-20 CU CU2012000012A patent/CU20120012A7/es active IP Right Grant
- 2012-01-20 GT GT201200012A patent/GT201200012A/es unknown
- 2012-01-20 DO DO2012000015A patent/DOP2012000015A/es unknown
- 2012-01-20 EC EC2012011616A patent/ECSP12011616A/es unknown
- 2012-01-20 CO CO12008148A patent/CO6491067A2/es active IP Right Grant
- 2012-01-20 CL CL2012000166A patent/CL2012000166A1/es unknown
- 2012-02-17 ZA ZA2012/01222A patent/ZA201201222B/en unknown
- 2012-11-30 HK HK12112380.9A patent/HK1171456A1/xx not_active IP Right Cessation
2013
- 2013-06-18 HR HRP20130558AT patent/HRP20130558T1/hr unknown
- 2013-06-26 CY CY20131100516T patent/CY1114260T1/el unknown
2015
- 2015-05-27 JP JP2015107399A patent/JP2015178522A/ja not_active Withdrawn
- 2015-06-04 US US14/731,232 patent/US9717739B2/en active Active
- 2015-11-12 DO DO2015000276A patent/DOP2015000276A/es unknown
2016
- 2016-03-28 JO JOP/2016/0059A patent/JO3732B1/ar active
2017
- 2017-02-06 JP JP2017019347A patent/JP6130087B1/ja not_active Expired - Fee Related
- 2017-04-04 US US15/478,803 patent/US10155004B2/en active Active
- 2017-11-21 HR HRP20171805TT patent/HRP20171805T1/hr unknown
- 2017-11-23 CY CY20171101228T patent/CY1119661T1/el unknown
2018
- 2018-06-22 EC ECSENADI201847708A patent/ECSP18047708A/es unknown
2019
- 2019-06-12 CY CY20191100611T patent/CY1121926T1/el unknown
- 2019-06-12 HR HRP20191049TT patent/HRP20191049T1/hr unknown

Also Published As

Publication number	Publication date
KR101687853B1 (ko)	2016-12-19
UA106502C2 (uk)	2014-09-10
WO2011009531A3 (de)	2011-04-28
PL2432798T3 (pl)	2013-08-30
RS52811B (en)	2013-10-31
MX2012000930A (es)	2012-03-26
HUE043757T2 (hu)	2019-09-30
HRP20171805T1 (hr)	2017-12-29
JP2017105813A (ja)	2017-06-15
US20120094969A1 (en)	2012-04-19
ES2416461T3 (es)	2013-08-01
IN2012DN00598A (da)	2015-06-12
ES2648292T3 (es)	2017-12-29
SG10201811830PA (en)	2019-02-27
LT2623510T (lt)	2017-12-11
EP2432798B1 (de)	2013-04-03
ZA201201222B (en)	2022-11-30
MY179447A (en)	2020-11-06
JP6130087B1 (ja)	2017-05-17
DE102009034362A1 (de)	2011-01-27
AR077491A1 (es)	2011-08-31
PL2623510T3 (pl)	2018-02-28
US20150342962A1 (en)	2015-12-03
CY1114260T1 (el)	2016-08-31
CA2768407A1 (en)	2011-01-27
EA201200121A1 (ru)	2012-07-30
HRP20130558T1 (hr)	2013-07-31
ME01534B (me)	2014-04-20
IL216967B (en)	2018-06-28
CR20170091A (es)	2018-02-06
HK1171456A1 (en)	2013-03-28
WO2011009531A2 (de)	2011-01-27
ME03400B (me)	2020-01-20
US10155004B2 (en)	2018-12-18
TR201908600T4 (tr)	2019-07-22
KR20120046182A (ko)	2012-05-09
SG10201404159VA (en)	2014-10-30
PT3252069T (pt)	2019-06-18
AU2010275849B2 (en)	2014-12-18
CN102482317B (zh)	2014-09-17
BR112012001344B8 (pt)	2021-05-25
DOP2012000015A (es)	2016-04-15
EP3252069A1 (de)	2017-12-06
NO2623510T3 (da)	2018-01-20
CO6491067A2 (es)	2012-07-31
CY1119661T1 (el)	2018-04-04
BR112012001344A2 (pt)	2016-03-15
MA33445B1 (fr)	2012-07-03
BR112012001344B1 (pt)	2020-09-24
CU24080B1 (da)	2015-03-30
TN2012000028A1 (en)	2013-09-19
DK3252069T3 (da)	2019-06-24
US8278469B2 (en)	2012-10-02
DOP2015000276A (es)	2018-04-15
PT2623510T (pt)	2017-11-24
JO3009B1 (ar)	2016-09-05
SI2432798T1 (sl)	2013-08-30
DK2623510T3 (da)	2017-12-04
CA2768407C (en)	2017-10-24
NZ623417A (en)	2015-10-30
CU20120012A7 (es)	2012-07-31
PE20121085A1 (es)	2012-08-04
HRP20191049T1 (hr)	2019-09-20
IL216967A0 (en)	2012-02-29
JP2012533575A (ja)	2012-12-27
ECSP18047708A (es)	2018-06-30
EP2623510A1 (de)	2013-08-07
PE20170084A1 (es)	2017-03-30
PT2432798E (pt)	2013-06-28
UY32791A (es)	2011-02-28
CY1121926T1 (el)	2020-10-14
GT201200012A (es)	2013-10-15
EA201301263A1 (ru)	2014-08-29
HN2012000137A (es)	2015-05-04
ES2730209T3 (es)	2019-11-08
US20170202857A1 (en)	2017-07-20
TWI505830B (zh)	2015-11-01
CR20120040A (es)	2012-03-12
EA025150B1 (ru)	2016-11-30
KR101854059B1 (ko)	2018-05-02
NZ597639A (en)	2014-04-30
EA021946B1 (ru)	2015-10-30
ECSP12011616A (es)	2012-02-29
CN102482317A (zh)	2012-05-30
KR20160093110A (ko)	2016-08-05
LT3252069T (lt)	2019-06-10
JO3732B1 (ar)	2021-01-31
EP3272763A1 (de)	2018-01-24
AU2010275849A1 (en)	2012-02-02
EP2432798A2 (de)	2012-03-28
SI3252069T1 (sl)	2019-06-28
US20120149670A1 (en)	2012-06-14
HUE037339T2 (hu)	2018-08-28
US9717739B2 (en)	2017-08-01
EP3252069B1 (de)	2019-04-03
SG177519A1 (en)	2012-02-28
CL2012000166A1 (es)	2012-08-31
JP5795312B2 (ja)	2015-10-14
EP2623510B1 (de)	2017-08-23
MX338217B (es)	2016-04-07
TW201105331A (en)	2011-02-16
PL3252069T3 (pl)	2019-09-30
SI2623510T1 (sl)	2017-12-29
JP2015178522A (ja)	2015-10-08

Publication	Publication Date	Title
DK2432798T3 (da)	2013-07-01	17-hydroxy-17-pentaflourethyl-estra-4,9(10)-dien-11-aryl-derivat, fremgangsmåde til fremstilling heraf og anvendelse heraf til behandling af sygdomme
DK2796469T3 (da)	2019-08-12	Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK2504005T3 (da)	2014-01-13	Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK2475372T4 (da)	2020-11-30	Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse
DK3428148T3 (da)	2020-08-31	Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf
LTC2144923I2 (lt)	2016-12-12	Gydymo būdas naudojant glikopegiliuotą G-CSF
DK3456707T3 (da)	2020-07-20	4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK2473034T3 (da)	2021-02-08	Frøbehandlingssammensætninger og fremgangsmåde
DK2300443T3 (da)	2013-02-18	Triazolderivater, der er anvendelige til behandling af sygdomme
DK2340042T3 (da)	2014-10-27	Fremgangsmåder og præparater til behandling af cancer
DK2509958T3 (da)	2014-10-20	Azolderivater, fremgangsmåder til fremstilling af disse, mellemprodukter deraf, midler til landbrug og gartnerier
BRPI0908026A2 (pt)	2015-07-21	Métodos para o tratamento de doenças do intestino
DK2247582T3 (da)	2017-01-02	Vandfri, krystallinsk form af dimethoxydocetaxel og fremgangsmåder til fremstilling heraf
DK2445912T3 (da)	2014-11-10	Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme
DK3196309T3 (da)	2019-11-25	Thraustochytrider, fedtsyresammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
DK2358669T3 (da)	2014-08-25	Alpha-keto-persyrer og fremgangsmåder til fremstilling og anvendelse heraf
DK2632954T4 (da)	2021-08-09	Midler og fremgangsmåder til behandling af dlbcl
DK2056842T3 (da)	2013-01-14	Modificeret galactosylceramid til behandling af cancerøse sygdomme
DK2639234T3 (da)	2019-09-23	Krystallinsk 6,7-umættet 7-carbamoylmorphinanderivat og fremgangsmåde til fremstilling heraf
DK2285808T3 (da)	2014-02-03	Spiroindolderivater til behandling af parasitsygdomme
DK2408807T3 (da)	2021-08-09	Fremgangsmåde til terapeutisk anvendelse
DK2010184T3 (da)	2013-03-25	Implatanter til behandlingen af dopamin associerede tilstande
DK2328417T3 (da)	2014-11-03	FORBINDELSER, PRÆPARATER OG FREMGANGSMÅDER TIL BEHANDLING AF beta-AMYLOIDSYGDOMME OG SYNUKLEINOPATIER
DK2448606T3 (da)	2013-08-05	Biologisk materiale, som er egnet til terapi af osteoarthrosis, ligamentskader og behandling af ledsygdomme.
BRPI0917684A2 (pt)	2015-12-01	método terapêutico homeopático